Patent ID: 7959922
Filing Date: 2011-06-14
Classification: A61K,A61P,C07K

Abstract:
1. A pharmaceutical formulation of anti-rabies monoclonal antibodies that is stable for at least 12 months at a temperature between about 2° C. to about 8° C., the formulation comprising: (i) anti-rabies virus monoclonal antibody CR57 (heavy chain SEQ ID NO: 1 and light chain SEQ ID NO: 2), or an antibody that is at least 95% homologous in sequence thereto and is capable of competing for binding to a target recognized by CR57 and having rabies virus neutralizing activity; and (ii) anti-rabies virus monoclonal antibody CR4098 (heavy chain SEQ ID NO: 3 and light chain SEQ ID NO: 4), or an antibody that is at least 95% homologous in sequence thereto and is capable of competing for binding to a target recognized by CR4098 and having rabies virus neutralizing activity; wherein the formulation comprises a citrate buffer at a concentration from about 5 mM to about 25 mM, sodium chloride at a concentration from about 50 mM to about 250 mM, and a surfactant.